Zacks.com on MSN4d
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease DrugThrough the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company ...
Sanofi is buying an immunology drug from Dren Bio, Inc. for up to $1.9 billion, in a deal it said will help it become a ...
Under the terms of the merger agreement, Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate ...
Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...
The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs ...
Pharmaceutical Technology on MSN4d
Sanofi outlays $1.9bn to purchase Dren Bio’s bispecific antibodySanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.
Sanofi (NASDAQ:SNY) has struck a major deal to acquire Dren Bios autoimmune disease treatment, DR-0201, reinforcing its ...
Sanofi is adding a new contender, agreeing to pay $600 million for a bispecific drug with an approach that could be first in class. The sum announced Thursday is an upfront payment for Dren Bio ...
As a drugmaker depending heavily on sales of both branded and non-branded products, Teva has said that it is uniquely affected by how medicines are selected for the Medicare drug price negotiation | ...
French drugmaker Sanofi has agreed to buy autoimmune disease therapy DR-0201 developed by Serbian-founded, US-based biotechnology firm Dren Bio, the two compani ...
The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback